Contrasting Citius Pharmaceuticals (NASDAQ:CTXR) & Relmada Therapeutics (NASDAQ:RLMD)

Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Citius Pharmaceuticals and Relmada Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1	2	1	0	2.00
Relmada Therapeutics	1	0	2	0	2.33

Citius Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 566.67%. Relmada Therapeutics has a consensus price target of $9.50, indicating a potential upside of 114.45%. Given Citius Pharmaceuticals’ higher probable upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Relmada Therapeutics.

Institutional and Insider Ownership

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Citius Pharmaceuticals and Relmada Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($3.37)	-0.27
Relmada Therapeutics	N/A	N/A	-$79.98 million	($1.80)	-2.46

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Citius Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Profitability

This table compares Citius Pharmaceuticals and Relmada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-55.93%	-31.00%
Relmada Therapeutics	N/A	-269.49%	-205.22%

Summary

Citius Pharmaceuticals beats Relmada Therapeutics on 6 of the 11 factors compared between the two stocks.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.